SUPN
NASDAQ · Pharmaceuticals
Supernus Pharmaceuticals Inc
$26.21
-0.53 (-1.98%)
Financial Highlights (FY 2026)
Revenue
1.19B
Net Income
347.68M
Gross Margin
144.9%
Profit Margin
29.2%
Rev Growth
+2.5%
D/E Ratio
0.45
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 144.9% | 144.9% | 44.7% | 44.7% |
| Operating Margin | 36.4% | 32.8% | 26.9% | 29.3% |
| Profit Margin | 29.2% | 27.8% | 19.5% | 20.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.19B | 1.16B | 1.12B | 1.08B |
| Gross Profit | 1.73B | 1.68B | 502.48M | 484.03M |
| Operating Income | 433.76M | 380.79M | 302.53M | 316.79M |
| Net Income | 347.68M | 305.22M | 218.96M | 223.93M |
| Gross Margin | 144.9% | 144.9% | 44.7% | 44.7% |
| Operating Margin | 36.4% | 32.8% | 26.9% | 29.3% |
| Profit Margin | 29.2% | 27.8% | 19.5% | 20.7% |
| Rev Growth | +2.5% | +2.5% | +10.9% | -8.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 866.66M | 866.66M | 863.19M | 832.43M |
| Total Equity | 1.91B | 1.91B | 1.94B | 2.13B |
| D/E Ratio | 0.45 | 0.45 | 0.45 | 0.39 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 433.79M | 401.97M | 345.29M | 368.42M |
| Free Cash Flow | — | — | 147.80M | 181.78M |